Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Passes User Fee Reauthorization With FDA/Industry Proposals Intact

This article was originally published in The Gray Sheet

Executive Summary

Legislation reauthorizing the medical device user fee program passed the Senate May 9. Action is now needed in the House to prevent the program from expiring on September 30

You may also be interested in...



Congress Approves FDA Reform/User Fee Bill In The Nick Of Time

Congress gave final approval last week to a massive FDA bill that renews device and drug user fees for five years and strengthens product safety programs

Congress Approves FDA Reform/User Fee Bill In The Nick Of Time

Congress gave final approval last week to a massive FDA bill that renews device and drug user fees for five years and strengthens product safety programs

FDA User Fee Reauthorization Bill Cleared For House Floor Action

A medical device user fee reauthorization bill was approved June 21 by the House Energy and Commerce Committee and cleared for floor debate. The legislation largely mirrors proposals previously negotiated by industry and FDA, with some additional amendments addressing postmarket safety concerns (see chart: "1Selected User Fee Bill Amendments From House Energy and Commerce Committee:")

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel